In vitro the behaviors of metastasis with suppression of VEGF in human bone metastatic LNCaP-derivative C4-2B prostate cancer cell line by Yang, L et al.
Yang et al. Journal of Experimental & Clinical Cancer Research 2012, 31:40
http://www.jeccr.com/content/31/1/40RESEARCH Open AccessIn vitro the behaviors of metastasis with
suppression of VEGF in human bone metastatic
LNCaP-derivative C4-2B prostate cancer cell line
Lei Yang1, Shuo You2, Vikas Kumar3, Chaoyue Zhang1 and Ya Cao4*Abstract
Background: Vascular endothelial growth factor (VEGF) is a signal protein produced by cells that stimulates
vasculogenesis and angiogenesis. VEGF is believed to implicate poor prognosis in various cancers. The
overexpression of VEGF may be an early step in the process of metastasis.
Methods: ELISA was used to investigate the levels of VEGF, bFGF and IL8 in human bone metastatic
LNCaP-derivative C4-2B prostate cancer cell line and its parental cell line, LNCaP and to determine the effect of
bevacizumab on reducing the level of VEGF. Cell proliferation assay, invasion assay and in vitro angiogenesis assay
were performed under the condition with bevacizumab or control IgG.
Results: Human bone metastatic LNCaP-derivative C4-2B prostate cancer cell line expressed a higher level of VEGF
than its parental primary prostate cancer cell line LNCaP. The effect of bevacizumab is dose-dependent and
time-dependent: 100 μg/mL of bevacizumab and 3-day treatment was more effective than low-dose and lesser-day
treatment for decreasing the level of VEGF. Bevacizumab is able to suppress cell proliferation, angiogenesis and
invasion in human bone metastatic C4-2B prostatic cancer cell line.
Conclusions: The overexpression of VEGF can be inhibited by bevacizumab in human bone metastatic cancer cell line.
The behaviors of metastasis involving proliferation, angiogenesis and invasion are suppressed by anti-VEGF therapy.
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Most of the time, when patients have cancer in their
bones, it is caused by metastatic cancer, or cancer that
has spread from elsewhere in the body to the bones. It is
much less common to have a primary bone cancer that
arises from cells that make up the bone. Surgery, chemo-
therapy and radiation therapy are the three main types of
treatment for bone cancer. Unfortunately, there are risks
and side effects associated with each of the treatments
for bone cancer. The main risks associated with surgery
include infection, recurrence of the cancer, and injury to
the surrounding tissues that may cause loss of sensation,
strength or function, or even cause amputation. The
medications of chemotherapy are designed to kill rapidly* Correspondence: ycao98@vip.sina.com
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reproduction in any medium, provided the ordividing or growing cells, but unfortunately normal cells
are also adversely affected. Radiation therapy damages
the surrounding skin and soft tissue and impairs wound
healing. There has been much recent advancement in the
understanding and treatment of bone cancer. This has
led to more focused radiation therapy to reduce the risk
to surrounding tissues, less side effects, and improved
treatment options, including limb-salvaging surgery, that
decrease the need for amputation. There is currently
much work being conducted in each of these areas as well
as investigations into the mechanisms of development of
metastatic cancer. It is hoped that a better understanding
of specific causes and mechanisms of metastatic cancer
will lead to advanced therapy that targets specific meta-
static cancer cells with limited risk to other normal cells.
Tumors are able to grow independently of vascularization
until they reach a size of approximately 2 mm. At this sized. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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nutrients and gas exchange, resulting in tumor dormancy
[1]. Continued growth requires tumor vascularization.
Cancer cells are able to induce angiogenesis by secreting
angiogenic factors including vascular endothelial growth
factor (VEGF) in order to activate certain actions by endo-
thelial cells [2]. Normally, endothelial cells divide infre-
quently, being held in check by angiogenesis inhibitors.
Once activated the endothelial cells secrete matrix-metal-
loproteases which begin to digest the extracellular matrix
surrounding the blood vessels. The endothelial cells
can then remodel the tissue. These migrating cells also
divide and increase in number, eventually organizing
into discrete tubules. Eventually these tubules connect
via anastomosis to form the neovasculature of the
tumor. The up-regulated VEGF promotes the activa-
tion of matrix-metalloproteases [3-5]. We hypothesize
that an anti-VEGF agent is able to maintain tumor dor-
mancy, and we aim to prove this hypothesis using
in vitro cell growth assay, angiogenesis assay and inva-
sion assay. For solid tumors, such as prostate cancer,
breast cancer and lung cancer, there is the chance that
the cancer will become advanced and spread to the
bone. In fact, for prostate cancer the bone is the most
common site of recurrence: approximately 80% of
prostate cancer recurrences are in the bone [6]. In this
study, we will report how anti-VEGF therapy affects
the growth and invasion of the bone metastatic prostate
cancer cell.
Materials and methods
Cell culture and reagents
Human bone metastatic prostate cancer C4-2B cell line is a
derivative of the LNCaP prostate cancer cell line with an-
drogen-independent characteristics. C4-2B cells were
obtained from ViroMed Laboratories, and LNCaP cells
were purchased from American Type Culture Collection
(Manassas, VA). Both C4-2B and LNCaP cells were main-
tained as monolayer cultures in RPMI 1640 medium sup-
plemented with 2 mM L-glutamine, 10% fetal bovine serum
and penicillin-streptomycin in a humidified atmosphere of
5% CO2 at 37°C. Human microvessel cells (VEC Technolo-
gies company, Rensselaer, New York) were cultured in
endothelial cell growth medium (PromoCell, Heidelberg,
Germany) in a humidified atmosphere of 5% CO2 at 37°C.
Bevacizumab (Genentech, San Francisco, CA) is a re-
combinant humanized monoclonal IgG1 antibody that
contains human framework regions and the complemen-
tarity-determining regions of a murine antibody that
binds to and inactivates all isoforms of VEGF.
VEGF, bFGF and IL-8 ELISA assays
The secretion of VEGF, basic fibroblast growth factor
(bFGF) and interleukin 8 (IL-8) by C4-2B cells to culturemedium was quantified by an enzyme-linked immuno-
sorbent assay (ELISA). A density of 2 × 105 of C4-2B,
LNCaP and human microvessel cells were separately
plated in a six-well plate. Human bone metastatic
prostate cancer C4-2B cells were also co-cultured with
human microvessel cells. All cultures were performed in
triplicate. When the cells reached 90% confluence on the
third day after they were seeded, the media were chan-
ged to complete culture media with 25 or 250 μg/mL
bevacizumab, or an equal amount of IgG1. The cell culture
media were collected at 72 hours after treatment in culture
medium with 2% FBS in 5% CO2 at 37°C. The levels of
VEGF, bFGF and IL-8 in the supernatants were measured
with an ELISA kit (Quantikine; R&D Systems, Minneapolis,
MN) according to the manufacturer’s instructions.Cell proliferation assay
A density of 5×103 cells per well was seeded on 96-
well-plate overnight in complete culture medium and
then treated with bevacizumab or control IgG or recom-
binant human VEGF in complete culture medium with-
out fetal bovine serum for a 3-day incubation. The cell
numbers were measured every 24 hours by mitochon-
drial 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2 H-tetrazolium, inner salt
(MTS) assay with use of the CellTiter 96 Aqueous One
Solution Cell Proliferation Assay (Promega) according to
the manufacturer’s instructions.Invasion assay
When C4-2B cells reached below 80% confluence, serum
containing medium was removed and replaced with
serum-free medium containing bevacizumab (100 μg/
mL) or an equal amount of IgG, and cultures were
returned to an incubator for 24 hours. The in vitro inva-
sion assay was performed with a 24-well collagen-based
cell invasion assay kit (Millipore). 2 × 105 of C4-2B cells
in 300 μl culture medium containing 100 μg/ml bevaci-
zumab or IgG were placed into an invasion chamber
consisting of a 24-well collagen-based plate. In order to
observe the direct role of VEGF on the invasion of C4-
2B cells, recombinant human VEGF (100 ng/ml)
was added to the lower chamber. The cells were incu-
bated for 24 h at 37°C in a 5% CO2 incubator. The non-
invading cells in the media were discarded from the top
of the insert. The invasive cells on the lower surface of
the membrane were stained by the green fluorescent dye
Calcein AM (Invitrogen) in PBS at 37°C for 1 h. The
fluorescently labeled cells were photographed under a
fluorescence microscope. The fluorescence of the
invaded cells was read by a microplate reader at excita-
tion/emission wavelength of 530/590 nm.
Figure 1 VEGF expression after in vitro treatment with
bevacizumab. Both 10 and 100 μg/mL bevacizumab decreased the
level of VEGF in C4-2B only, compared with control IgG. There were
significant differences in the VEGF levels between the 10 or 100ug/ml
bevacizumab and control IgG (P< 0.01). Human bone metastatic
prostate cancer cell co-cultured with human microvessel cell expressed
6 times more VEGF than did tumor cultured cell only, and this level
significantly decreased after treatment with 10 or 100 μg/mL
bevacizumab.
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When C4-2B cells reach 80% confluence, they were cul-
tured in serum-free RPMI1640 treated with bevacizumab
(100 μg/mL) or an equal amount of IgG for 24 h. The
conditioned media were collected, centrifuged, and
transferred to fresh tubes. Human microvessel cells were
maintained in complete media and starved for 4 h, were
trypsinized and seeded in each well with conditioned
culture medium from C4-2B with 100 μg/mL bevacizu-
mab or an equal amount of IgG1 on growth factor-con-
taining ECMatrixgel (Millipore, Billerica, MA) in a 24-
well-plate, incubated in 5% CO2 at 37°C for 10 hours,
and inspected for tube formation with an inverted light
microscope (Olympus, Tokyo, Japan). Three random
fields per well were examined at 40× magnification, and
the values were averaged. The pattern/value association
criteria for tube formation are: 0, individual cells, well
separated; 1, cells beginning to migrate and align them-
selves; 2, capillary tubes visible without sprouting; 3,
sprouting of new capillary tubes; 4, closed polygons be-
ginning to form; and 5, complex meshlikestructures
developing. Each well was photographed using an
inverted microscope with a digital camera. The images
were taken at 10× magnification and the total lengths of
the tubes were measured with Image J (Image Processing
Analysis in Java, ver. 1.42; developed by Wayne Rasband,
National Institutes of Health, Bethesda, MD; available at
http://rsb.info.nih.gov/ij/index.html).
Statistical analysis
Comparison between the two groups was performed
using the student’s t-test. A P value of less than 0.05 was
considered significant and a P value of less than 0.01
was considered highly significant. Microsoft® Office
Excel 2003 SP3 was used for data analysis.
Results
Expression of VEGF, bFGF and IL-8
To screen for the expression of angiogenic factors in
prostate cancer cell and its bone metastatic cell, three
angiogenic factors in conditioned media were detected
with ELISA. The secreted VEGF by the parental LNCap
cell line and its derived bone metastatic cell line C4-2B
was detected. The production of bone metastastic cell
line C4-2B (294.47 ± 31.99 pg/ml) was significantly
higher than its parental cell line LNCap (204.40 ±
23.32 pg/ml, P = 0.016). The secreted bFGF and IL-8
protein were not detected in bone metastatic cell line
C4-2B and its paretental LNCap cell line by EILSA.
Bevacizumab suppressed VEGF from C4-2B and
microvessel cells
To determine the concentration of bevacizumab needed
for neutralizing the secreted VEGF by bone metastaticprostate cancer C4-2B cell line, ELISAs were performed
to measure the levels of VEGF in conditioned media in
C4-2B and C4-2B co-cultured with microvessel cells
under bevacizumab or control IgG treatment. The level
of VEGF from cells with bevacizumab or control IgG
treatment is shown in Figure 1. The level of VEGF
secreted by human bone metastatic prostate cancer
C4-2B cell line co-cultured with microvessel cells
was much greater than that secreted by C4-2B only.
Both 10 and 100 μg/ml bevacizumab decreased the
level of VEGF secreted by C4-2B, compared with
control IgG. There were significant differences in the
VEGF levels between the 10 or 100 ug/ml bevacizu-
mab and control IgG (P< 0.01). Treatment with
100 μg/ml bevacizumab caused a more pronounced
decreased in VEGF than treatment with 10 μg/ml
bevacizumab. The level of VEGF was significantly
increased when tumor cells were co-cultured with
vascular endothelium. The levels of VEGF in co-culture
media were 5.97 times greater than that in medium from
C4-2B only. VEGF was reduced in C4-2B to 187.53 ±
23.79 pg/mlafter treatment with 10 μg/ml bevacizumab
and 91.06 ± 19.82 pg/ml after treatment with 100 μg/ml
bevacizumab, and in C4-2B co-cultured with microvessel
cell VEGF was reduced to 949.42 ± 177.88 pg/ml after
treatment with 10 μg/ml bevacizumab and 297.20 ±
69.27 pg/ml after treatment with 100 μg/ml bevacizu-
mab,. There were significant differences in the VEGF
levels between the 10 and 100 μg/ml bevacizumab
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Figure 1). A high concentration of bevacizumab was
more effective than a low concentration on reducing
VEGF in C4-2B cells and C4-2B cells co-cultured with
microvessel cells.
Bevacizumab inhibited cell proliferation in C4-2B
Because the increased production of VEGF drives angio-
genesis related to tumor progression, we investigate the
possibility that neutralization of VEGF may interrupt by
the growth of bone metastatic prostate cancer C4-2B
cell line. When C4-2B cells were exposed to bevacizu-
mab (0, 10, 100 μg/ml) for a 2-day incubation, the
growth of C4-2B was inhibited in a concentration-
dependent manner, whereas the control IgG did not
affect the growth C4-2B cells, and VEGF enhanced
the proliferation of C4-2B cells (Figure 2a). At day 3
bevacizumab (100 μg/ml) inhibited the proliferation
of C4-2B cells by 83% (Figure 2b). These data sug-
gest that bevacizumab significantly inhibited cell
proliferation in bone metastatic prostate cancer cells.Figure 2 Bevacizumab inhibits the growth of bone metastasis prostat
inhibited the cell proliferation of C4-2B in a dose-dependent manner after
(100 μg/ml) did not decrease the growth of C4-2B. cells. VEGF (100 ng/ml)
the inhibitory proliferation of C4-2B was gradually increased with a time-de
bevacizumab treatment. **means P< 0.01, significant differences from theBevacizumab suppressed of angiogenesis in vitro
Based on the effect of different concentrations of bevaci-
zumab on the proliferation in C4-2B cells, 100 μg/ml of
bevacizumab would be used in the angiogenesis and in-
vasion assay in vitro. Human microvessel cells developed
complex meshlike structure patterns (grade 5) when
grown in a growth-factor gel matrix. At 10 hour after
control IgG treatment, the cells formed complex mesh-
like structure patterns (Figure 3, left). After treatment
with bevacizumab (100 μg/ml), the cells showed a migra-
tion/alignment pattern (grade 1, Figure 3, right). The
average total capillary tube length in human microvessel
cells with IgG, or bevacizumab (100 μg/ml) was
1255.31 ±134.90 and 195.04 ± 26.67 μm, respectively
(P< 0.01).
Bevacizumab reduced C4-2B cell invasion
The level of VEGF is known to correlate with prostate
cancer invasion and metastasis in bone. We performed
in vitro invasion assay to estimate whether bevacizumab
reduced C4-2B cell invasion. RPMI-1640 without FBSe cancer cell line C4-2B. a. Different concentrations of bevacizumab
2-day incubation determined by mitochondrial MTS assay. Ig G
enhanced the growth of C4-2B cells. b. The effect of bevacizumab on
pendence. The relative fold was assigned as 1.0 in the absence of
bevacizumab treated with untreated group.
Figure 3 Suppressed tube formation of human microvessel by conditioned media from C4-2B cells treated with bevacizumab (right) or
control IgG (left).
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ground control, RPMI-1640 with 5%FBS was added to
the lower chamber and C4-2B cells without treatment
were added to the upper chamber as a positive control.
In order to express the direct role of VEGF on the inva-
sion of C4-2B cells, the recombinant human VEGF as a
chemoattractant was added to the lower chamber. VEGF
induced C4-2B cells to invade through the Marigel. In
the absence of VEGF, the invasion was very low. With
100 μg/ml of bevacizumab in the upper chamber, signifi-
cantly less numbers of C4-2B cells migrated into the
lower chamber, and IgG1 did not inhibit the invasion
(Figure 4a and b). The result of the fluorescence micro-
plate reader showed that the fluoresence intensity in the
chamber with bevacizumab (100 μg/mL) was signifi-
cantly lower than that in the chamber with control
IgG1 (Figure 4c). Bevacizumab was high significantly
decreased C4-2B cell invasion, comparing with con-
trol IgG (Figure 4, P< 0.01)
Discussion
In solid tumor, such as prostate cancer, there is the chance
that the cancer will become advanced and spread to the
bone. In prostate cancer, the most common site of a re-
currence is the bone. In fact, approximately 80% of pros-
tate cancer recurrences are in the bone [6]. If the cancer
metastasizes to distant sites, the 5-year survival rate is the
only 31%. Importantly, once tumors metastasize to bone,
they are virtually incurable and result in significant disease
morbidity prior to a patient’s death. Bone metastases can
lead to pain, pathological fractures, nerve compression
syndromes, and hypercalcemia. Current treatments are
mainly palliative. Despite the high incidence and serious
consequences of skeletal metastasis of prostate cancer, the
mechanism underlying this osteotropism is unclear. How-
ever, it is clear that VEGF has been implicated in various
carcinogenesis and metastasis as well as in angiogenesis.VEGF is expressed by prostate cancer at a high level [7-9],
and its expression correlates with increasing grade, vascu-
larity, and tumorigenicity [9,10]. These relationships have
been observed in human as well as in animal models of
prostate cancer. High VEGF levels in prostate cancer are
associated with poor prognosis. In addition, VEGF pro-
duced by tumor cells affects bone remodeling and might,
therefore, facilitate nesting of metastatic cells in bone [11].
Bevacizumab is a recombinant, humanized monoclonal
antibody that inhibits the binding of vascular endothelial
growth factor (VEGF) to its receptors. Several experimental
studies have examined the extent to which VEGF inhibitors
or VEGF targeted agents prevent tumor cell growth and
metastasis in vitro and in vivo [12-20]. In this study, we
focus on the effect of bevacizumab on human bone meta-
static LNCaP-derivative C4-2B prostate cancer cell line.
Angiogenesis is one of the critical events required in the
cancer metastatic process. VEGF is a specific stimulator of
vascular endothelial cell proliferation and tumor angiogen-
esis. VEGF is produced in response to various cellular and
environmental stimuli. VEGF is overexpressed in many
human neoplasms [4,5,7,9,20-22]. This expression is asso-
ciated with increased tumor size, necrosis and tumor angio-
gensis. New blood vessels that grow within the tumor
secondary to VEGF expression are structurally and func-
tionally irregular, as they exhibit dead ends, disordered
blood flow, and increased permeability. These irregularities
in blood flow lead to further tumor hypoxia and subsequent
increases in VEGF production [23,24]. In this study, we
confirm that human bone metastatic prostate cancer cell
line C4-2B has a higher level of VEGF than its parental cell
line LNCaP, although both of cell lines have high levels of
VEGF expression. We found that VEGF production signifi-
cantly increased 6-fold when bone metastatic prostate can-
cer cells were cocultured with vascular endothelium.
VEGF exhibits the effects on the growth and progres-
sion of neoplasia. Several studies have shown a correlation
Figure 4 Bevacizumab reduced the ability of invasion in C4-2B (b), comparing with an equal amount of IgG treatment (a). In the
invasion assay, we seeded cells on the top of the Matrigel and added VEGF to the lower chamber. Invasive cells penetrate Matrigel and end up
on the other side of the Matrigel. We estimated invasion by measuring the fluoresence intensity in the fluorescence microplate reader and
counting the number of invading cells, and setting the average of invading cell numbers of C4-2B with VEGF added to the lower chamber as
100%. The results showed that VEGF-mediated invasion of C4-2B was suppressed by bevacizumab, and not by IgG1. (P< 0.01, Figure 4c).
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[16-23]. Recent studies have indicated that bevacizumab
treatment results in a dose-dependent inhibition of tumor
growth in vitro and in vivo [18,24,25]. In our study, beva-
cizumab gave a dose-dependent and time-dependent re-
duction of cell proliferation in human bone metastatic
prostate cancer cells.
Metastasis is an extraordinarily complex process. To
successfully colonize a secondary site a cancer cell
must complete a sequential series of steps before it
becomes a clinically detectable lesion. These steps
typically include separation from the primary tumor,
invasion through surrounding tissues and basement
membranes, entry and survival in the circulation, and
arrest in a distant target organ. These are usually, but
not always, followed by extravasation into the sur-
rounding tissue, survival in the foreign microenviron-
ment, proliferation, and induction of angiogenesis.
The treatment against any steps may affect the forma-
tion of metastasis. Our results show bevacizumab sig-
nificantly decreases the ability of invasion andangiogenesis formation in human bone metastatic
prostate cancer cells.
Conclusions
In conclusion, anti-VEGF therapy has an inhibitory
effect on human bone metastatic prostate cancer cells.
Neutralization of VEGF disturbs the multistep process
of metastasis including proliferation, angiogenesis and
invasion. Anti-VEGF therapy is a potential adjuvant
treatment strategy for the treatment of human bone
metastatic cancer.
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